ARBORXR
7.10.2021 16:55:09 CEST | Business Wire | Press release
ArborXR , the leading enterprise AR/VR device management and content distribution platform, and AR/VR solutions distributor, Matts Digital , today announced a partnership to provide frictionless extended reality (XR) solutions at scale in Europe and beyond. With ArborXR’s mobile device management (MDM) software, Matts Digital will help companies securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset user experience. The partnership illustrates an accelerated shift to remote work and training amid the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005755/en/
According to Forbes , global spending on AR/VR rose to $12 billion in 2020, up 50 percent from 2019.
“ArborXR and Matts Digital share a mission to help companies use and scale XR technology with ease, while offering exceptional customer service,” said ArborXR Co-Founder Will Stackable. “By partnering with Matts Digital, ArborXR is able to help global enterprise companies succeed and increase efficiency through the power of XR. We’re thrilled to enter the European market and provide vital software to help companies deploy AR/VR with confidence.”
Matts Digital offers an extensive range of AR/VR products, in addition to unique XR technology professional services. By utilizing ArborXR’s software, Matts Digital will help companies manage thousands of devices with security and control.
“Matts Digital is pleased to work with ArborXR to offer best-in-class XR solutions for a variety of global companies. Together, we will help customers use XR devices with confidence and achieve our shared goal to increase the simplicity, security and efficiency of XR in the workplace,” Matts Digital President Stephane Courgeon said.
To learn more about ArborXR or Matts Digital, visit ArborXR.com or Matts-Digital.com .
About ArborXR
ArborXR is AR/VR mobile device management (MDM) software that allows enterprise companies to securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset experience. It is used by Fortune 500 companies, businesses, and hundreds of independent software vendors to seamlessly manage devices, enroll and provision headsets, deploy apps and files remotely, and lock down the user experience with kiosk mode and a multi-app launcher. Learn more about ArborXR and its recent completion of a Series A at ArborXR.com .
About Matts Digital
Matts Digital is a Value-Added distributor, specializing in Virtual Reality (VR) and Augmented Reality (AR) solutions. We offer a full range of headsets, peripherals, accessories and hygiene products, as well as unique professional services in this area. Our significant industrial and logistical capacity allows our customers to easily consider the deployment of their ARVR projects on a large scale, in France and abroad. Learn more at Matts-Digital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom